CN Patent

CN106316963B — 吗啡啉苯基氨基嘧啶化合物或其盐的多晶型物

Assigned to Suzhou Zelgen Biopharmaceutical Co Ltd · Expires 2021-06-08 · 5y expired

What this patent protects

本发明涉及吗啡啉苯基氨基嘧啶化合物或其盐的多晶型物，更具体地，涉及N‑(氰基甲基)‑4‑(2‑(4‑(吗啡啉苯基氨基)嘧啶‑4‑基)苯甲酰胺、或其药学上可接受的盐，或其溶剂合物的多晶型物。所述多晶型物适合用于制备抑制非受体酪氨酸激酶(如JAK激酶)的药物组合物。

USPTO Abstract

本发明涉及吗啡啉苯基氨基嘧啶化合物或其盐的多晶型物，更具体地，涉及N‑(氰基甲基)‑4‑(2‑(4‑(吗啡啉苯基氨基)嘧啶‑4‑基)苯甲酰胺、或其药学上可接受的盐，或其溶剂合物的多晶型物。所述多晶型物适合用于制备抑制非受体酪氨酸激酶(如JAK激酶)的药物组合物。

Drugs covered by this patent

Patent Metadata

Patent number
CN106316963B
Jurisdiction
CN
Classification
—
Expires
2021-06-08
Drug substance claim
No
Drug product claim
No
Assignee
Suzhou Zelgen Biopharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.